Evidence map›Paper›PMID 20454968›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2010

Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice.

Ralf Koester, Jan Kaehler, Henning Ebelt, Gerold Soeffker, Karl Werdan, Thomas Meinertz

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012
    Trial
  4. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina.Clinical research in cardiology : official journal of the German Cardiac Society · 2012
    Trial
  5. Trial
  6. Trial
  7. Ivabradine for the treatment of stable angina pectoris in octogenarians.Clinical research in cardiology : official journal of the German Cardiac Society · 2011
    Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Ivabradine: potential clinical applications in critically ill patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2013
    Review
  14. Is heart rate a treatment target in heart failure?Current cardiology reports · 2012
    Review
  15. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012
    Article
  16. Review
  17. Heart rate reduction in cardiovascular disease and therapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2011
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ralf KoesterClinic for General and Interventional Cardiology, University Heart Center Hamburg, Germany. rkoester@uke.uni-hamburg.de
Jan Kaehler
Henning Ebelt
Gerold Soeffker
Karl Werdan
Thomas Meinertz
University Cancer Center Hamburg · DEUniversity Hospital in Halle · DEUniversität Hamburg · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe anti-anginal efficacy of the selective I(f) inhibitor ivabradine has been demonstrated in controlled clinical trials. However, there is limited information about the safety and efficacy of a combined treatment of ivabradine with beta-blockers, particularly outside of clinical trials in every day practice. This analysis from the REDUCTION study evaluated the safety and efficacy of a combined therapy of beta-blockers and ivabradine in every day practice.

methodsIn this multi-center study 4,954 patients with stable angina pectoris were treated with ivabradine in every day routine practice and underwent a clinical follow-up for 4 months. 344 of these patients received a co-medication with beta-blockers. Heart rate (HR), angina pectoris episodes, nitrate consumption, overall efficacy and tolerance were analyzed.

resultsAfter 4 months of treatment with ivabradine HR was reduced by 12.4 ± 11.6 bpm from 84.3 ± 14.6 to 72.0 ± 9.9 bpm, p < 0.0001. Angina pectoris episodes were reduced from 2.8 ± 3.3 to 0.5 ± 1.3 per week, p < 0.0001. Consumption of short-acting nitrates was reduced from 3.7 ± 5.6 to 0.7 ± 1.7 units per week, p < 0.0001. Five patients (1.5%) reported adverse drug reactions (ADR). The most common ADR were nausea and dizziness (<0.6% each). There was no clinically relevant bradycardia. Efficacy and tolerance were graded as 'very good/good' for 96 and 99% of the patients treated.

conclusionIvabradine effectively reduces heart rate and angina pectoris in combination with beta-blockers and is well tolerated by patients in every day practice.

Indexed as

Adrenergic beta-AntagonistsAgedAngina PectorisBenzazepinesDrug Therapy, CombinationFemaleHumansIvabradineMaleMembrane Transport ModulatorsMiddle AgedTreatment OutcomeAdrenergic beta-AntagonistsBenzazepinesIvabradineMembrane Transport Modulators

Identifiers

PMID20454968
OpenAlexW2012733260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.